The 2026 Nobel Prize in Physiology or Medicine was announced on 5 October at the Karolinska Institutet in Stockholm. It is shared equally by Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg, for discoveries concerning light-gated ion channels and optogenetics.
The idea behind the jargon fits in one sentence: in a living brain, a chosen type of nerve cell can be switched on or off with light. According to the Nobel committee, researchers have used this to map the circuits behind specific memories, feelings and behaviours.
What is optogenetics?
Optogenetics means putting a light-sensitive protein into a nerve cell and then controlling that cell with light. The protein is carried in by a gene, and because the gene can be set up to work in only one cell type, the neighbouring cells ignore the light.
Picture the brain as a hall with thousands of lamps. A classic electrode is like flipping the breaker for one corner: every lamp nearby comes on. Optogenetics fits a separate switch to just the lamps you care about, and that switch works within milliseconds, fast enough to keep up with neurons.
Where did the light-sensitive protein come from?
From green algae. The single-celled alga Chlamydomonas steers towards light using proteins in its membrane. In papers published in Science in 2002 and PNAS in 2003, Nagel and Hegemann described two of them, channelrhodopsin-1 and channelrhodopsin-2, and showed that they are ion channels that open when light hits them. An ion channel is a tiny gate in the membrane; when it opens, charged particles flow through, and in a neuron that flow triggers a signal.
In 2005, Deisseroth's group at Stanford, with Nagel among the co-authors, reported in Nature Neuroscience that channelrhodopsin-2 delivered into mammalian neurons made them fire on cue with pulses of light, at millisecond precision. Nobody studying how an alga finds light had been looking for a brain tool.
What did it change in memory research?
It made cause and effect testable. Brain imaging shows which regions are active during a task, but activity alone does not prove a region does the job. Switching the cells yourself shows whether behaviour actually changes.
In a frequently cited 2012 Nature study from Susumu Tonegawa's lab at MIT, the team tagged hippocampal cells that were active while mice learned to fear a particular place. Later, in a different and harmless setting, switching those cells on with light made the mice freeze, as if they were recalling the fear. Our pieces on neuroplasticity and the 10 percent brain myth fill in the background.
Is optogenetics used to treat patients?
Only experimentally so far. In the best-known case, published in Nature Medicine in 2021 by Sahel and colleagues, a man blinded by the inherited eye disease retinitis pigmentosa received a gene for a light-sensitive protein in one eye. Wearing special goggles that turn changes in the scene into light pulses aimed at the retina, he could locate, touch and count objects on a table. Without the goggles, nothing changed.
One patient, partial vision, a device required: a promising start rather than an available therapy. Inside the brain the hurdles are higher. Animal studies usually deliver light through a thin optical fibre, which in a person would mean gene delivery plus surgery.
How should you read optogenetics headlines?
Expect more of them after the prize. Check which animal the study used, how many subjects it had, and whether the result is a lab measurement or a difference in everyday life. Stimulating cells in a mouse and treating a disease in a person are usually years apart. Seeing "in mice" in the first paragraph does not make a story worthless; it tells you which shelf to put it on.